Polaryx Therapeutics, Inc.
PLYX
$2.08
$0.062.97%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -48.32% | 264.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -29.52% | 114.93% | |||
| Operating Income | 29.52% | -114.93% | |||
| Income Before Tax | 45.75% | -70.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 45.75% | -70.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 45.75% | -70.17% | |||
| EBIT | 29.52% | -114.93% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 46.94% | -68.97% | |||
| Normalized Basic EPS | 46.88% | -69.35% | |||
| EPS Diluted | 46.94% | -68.97% | |||
| Normalized Diluted EPS | 46.88% | -69.35% | |||
| Average Basic Shares Outstanding | 2.24% | 0.74% | |||
| Average Diluted Shares Outstanding | 2.24% | 0.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||